Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Red yeast rice capsule (LipoCol Forte)is a nature product that has been demonstrated a
significant cholesterol lowering effect which might be caused by addictive and/or synergistic
effects of lovastatin (monacolin K) with other monacolins and substances in capsules. The
usual dose of red yeast rice capsule(LipoCol Forte)for hypercholesterolemia is one capsule
twice/day.
Gemfibrozil is a fibric acid derivative (fibrate). It can reduce the levels of triglycerides
and increase the levels of high-density lipoprotein cholesterol (HDL-C). Patients with mixed
lipid disorders may therefore benefit from a combination of a statin and a fibrate. Although
the combination of a fibrate and a statin is highly effective,concerns about an increased
incidence of myopathy and even rhabdomyolysis have limited the widespread use of such
combinations. Such combination therapies are prone to drug-drug interactions, which can lead
to altered pharmacokinetic profiles of either drug, an effect observed for many statins in
combination with fibrates. However, the drug-drug interactions have not been reported between
red yeast rice capsule and gemfibrozil.
The objective of the study is to evaluate the effect of gemfibrozil on the plasma
concentrations of lovastatin and its active form, lovastatin acid, from red yeast rice
capsule in healthy volunteers. In addition, the investigators also measure the plasma
concentration of creatine kinase (CK) and co-enzyme Q10 for safety assessment.